---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-25-000044"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T10:26:58.554390+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INNOVATE Q1 revenue $274.2M (-13% YoY); net loss widens to $24.8M; MediBeacon TGFR gets FDA approval

## Summary
- Revenue $274.2M, down 13% YoY; net loss attributable to common $24.8M ($1.89 per share), vs $17.7M loss YoY.
- DBM Global revenue $264.9M (-14% YoY); adjusted backlog $1.4B, added over $500M in new awards.
- MediBeacon TGFR system received FDA approval in Jan to assess kidney function; also NMPA China approval.
- Life Sciences R2 revenue tripled to $3.1M; unit sales up 163% YoY.
- Spectrum revenue $6.2M; signed contract for two new OTA networks; datacasting revenue expected by year-end.

## SEC filing metadata
- accession: 0001006837-25-000044
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000044/0001006837-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000044/hchc-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-25-000044
- JSON: https://secwatch.observer/filing/0001006837-25-000044.json
- Plain text: https://secwatch.observer/filing/0001006837-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.